Court Report - February 26, 2012

more+
less-

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Cellectis S.A. v. Precision Biosciences Inc.
1:12-cv-00204; filed February 21, 2012 in the District Court of Delaware

Declaratory judgment of invalidity and non-infringement of U.S. Patent Nos. 8,119,361 ("Methods of Cleaving DNA with Rationally-Designed Meganucleases," issued February 21, 2012) and 8,119,381 ("Rationally Designed Meganucleases with Altered Sequence Specificity and DNA-Binding Affinity," issued February 21, 2012).  View the complaint here.

Precision BioSciences, Inc. v. Cellectis SA et al.
5:12-cv-00076; filed February 20, 2012 in the Eastern District of North Carolina

• Plaintiff:  Precision BioSciences, Inc.
• Defendants:  Cellectis SA; Cellectis bioresearch; Cellectis bioresearch Inc.

Infringement of U.S. Patent No. 8,119,361 ("Methods of Cleaving DNA with Rationally-Designed Meganucleases," issued February 21, 2012) based on Cellectis' manufacture, use, and sale of certain products, including meganucleases targeting the HIV1 genome.  View the complaint here.

Please see full update below for more information.

LOADING PDF: If there are any problems, click here to download the file.


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Written by:

more+
less-

McDonnell Boehnen Hulbert & Berghoff LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
×
Loading...
×
×